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Introduction
Skin cancer patients are known to be at increased risk of developing subsequent skin cancers due to shared risk factors: large parts of their skin have usually been exposed to mutagenic changes as a result of exposure to UV radiation or other carcinogens. This so-called field cancerization 1 in combination with the generally good prognosis of adequately treated skin cancer gives ample opportunity for new skin cancers to develop. Other shared risk factors like genetics 2 and immune suppression 3 might further increase the occurrence of subsequent skin cancers. Two meta-analyses reported pooled risks for a subsequent melanoma or keratinocyte carcinoma (KC, including squamous cell carcinoma [SCC] and basal cell carcinoma, [BCC] ) in melanoma and KC patients. A previous melanoma was shown to be a strong predictor for development of a subsequent melanoma (pooled standardized incidence ratio [SIR]: 10.4) and to a lesser extent of a subsequent KC: SIR 2.8-4.6. 4 A prior KC is a very strong predictor of a subsequent KC, with a mean 5-year cumulative risk 36 .2% and to a less extent melanoma (pooled proportion 0.5%). 5 The majority of previous studies, included in the meta-analyses or published thereafter, only reported proportions of patients developing subsequent skin cancers. Proportions are quite an uninformative measure as they provide no insight into the behaviour of the risk over time, neither they provide an estimate of excess risk compared to the general population. Very few studies reported the preferable SIR which provides a risk relative to that of the general population (i.e. relative risk of subsequent skin cancer) or cumulative risks (i.e. risks during followup time correcting for risk of death). Some studies reported incidence rates or hazard ratios 6 to describe risks of subsequent skin cancers, which are relatively difficult to interpret for patients and clinicians. In this study, the risks (cumulative risk, standardized incidence ratio [SIR] and absolute excess risk [AER]) of developing a subsequent melanoma, SCC or BCC after a first melanoma or KC were investigated in Dutch population-based cohorts between 1989 and 2009 and stratified by follow-up periods, age categories and sex. The estimates may serve as information for patients and clinicians, healthcare policymakers and public health campaigns.
Methods

Data
The population-based Netherlands Cancer Registry (NCR) provided national incidence data of all patients diagnosed with a primary invasive cutaneous melanoma or SCC between 1989 and 2009 (BCCs were not registered in the NCR during the study period). The regional population-based Eindhoven Cancer Registry (ECR) provided incidence data of all patients diagnosed with a primary invasive cutaneous melanoma, SCC Person-years at risk were calculated as time since diagnosis of the first cutaneous malignancy until the date of diagnosis of a subsequent primary cutaneous malignancy, date of death or end of follow-up (December 31 2009), whichever comes first. Of note, all the subsequent cutaneous malignancies were included. For instance, after a first BCC diagnosis, if the second cancer was a SCC and the third was a melanoma, this SCC was included in the BCC-SCC tumour combination; the melanoma was included in the BCC-melanoma tumour combination, and so forth for other rank cancers. Patients were excluded if other invasive cancers were diagnosed before the first primary cutaneous malignancy and when patients did not have any follow-up time (n = 135). Patients aged less than 15 years or over 95 years at diagnosis of the first primary cutaneous malignancy (n = 772) were excluded from the analyses.
Statistical analysis
Cumulative risk of subsequent cutaneous malignancy up to 21 years after diagnosis of the first cutaneous malignancy was calculated taking the competing risk of death into account. 9 The standardized incidence ratio (SIR) is the ratio between the observed number of subsequent cutaneous malignancy and the expected number from the general population. It is a useful multiplicative measure for determining excess risk of subsequent cutaneous malignancy relative to the background risk in the general population. To derive the expected numbers, person-years under age-specific (5-year band), calendar-specific (1-year band) and sex-specific stratum were multiplied with the corresponding background incidence rate from the general Dutch population. A SIR >1 indicates that the risk of developing a subsequent cutaneous malignancy is higher among the skin cancer patients than in the general population. Absolute excess risk (AER) is an absolute measure for determining additional incidence beyond background incidence due to occurrence of subsequent cutaneous malignancies. It is expressed as the difference between the observed number and the expected number of cases per 10 000 person-years (i.e. [O-E]/person-years at risk 9 10 000). Both SIR and AER were illustrated under age categories (<50, 50-64, 65-74, >75 years) and follow-up periods of 0-1 year, 2-5 years, 6-10 years and 11-21 years after the first skin cancer diagnosis. The 95% CI was under Poisson distribution, and the statistical significance level was estimated at two-sided at 0.05. All analyses were performed using SAS 9.3 statistical software (SAS Institute, (47) 1420 (4) 1246 (5) 961 (40) 1674 (50) 174 (5) 143 (6) 2,919 (14) 4,269 (20) 50-64 years 7361 (35) 7976 (27) 7165 (19) 4275 (16) 850 (35) 948 (28) 769 (22) 449 (20) 6990 (35) 6642 (31) 65-74 years 3646 (17) 3829 (13) 11 447 (30) 5870 (22) 418 (17) 401 (12) 1078 (31) 543 (24) 5963 (30) 4934 (23) >75 years 2195 (10) 3696 (13) 17 724 (47) 14 907 (57) 193 (8) 331 (10) 1453 (42) 1140 (50) 4246 (21) 5522 (26) Location 1st diagnosis Head and neck 3260 (15) 3054 (11) 28 787 (76) 15 539 (59) 349 (14) 344 (10) 2606 (75) 1315 (58) 14 312 (71) 14 606 (68) Trunk 10 120 (47) 7668 (26) 2003 (5) 2129 (8) 1181 (50) 941 (28) 217 (6) 232 (10) 3627 (18) 3,813 (18) Arms 3510 (16) 6201 (21) 5211 (14) 4807 (18) 364 (15) 727 (22) 537 (15) 453 (20) 1400 (7) 1392 (6) Legs 3431 (16) 11 464 (39) 1344 (4) 3531 (14) 396 (16) 1245 (37) 102 (3) 261 (11) 685 (3) 1470 (7) Other/unknown 1017 (5) 785 (3) 411 (1) 292 (1) 132 (5) 97 (3) 12 ( (16) 57 (19) 67 (23) 37 (23) 57 (34) 63 (26) 130 (25) 77 (31) 39 (30) 31 (27) 2-5 years 139 (40) 97 (33) 116 (40) 60 (38) 53 (31) 73 (30) 201 (40) 84 (34) 46 (36) 46 (39) 6-10 years 99 (28) 79 (27) 58 (20) 35 (22) 39 (23) 63 (26) 110 (22) 58 (23) 19 (15) 22 (19) 11-21 years 56 (16) 64 (21) 50 (17) 26 (17) 20 (12) 44 (18) 66 (13) 31 (12) 24 (19) 18 (15) Subsequent SCC
0-1 year
158 (21) 80 (22) 2-5 years 230 (31) 126 (34) 6-10 years 203 (27) 86 (24) 11-21 years 152 (21) 74 (20) NCR, Netherlands Cancer Registry; ECR, Eindhoven Cancer Registry; SCC, Squamous cell carcinoma; BCC, Basal cell carcinoma; FU, Follow-up until death or lost-to-follow-up; IQR, Interquartile range. 
Results
Cohort characteristics
The national data of the NCR consisted of 50 510 patients with a first primary invasive melanoma and 64 054 patients with a first primary squamous cell carcinoma of the skin. The regional data of the ECR contained 5776 melanoma patients, 5749 SCC patients and 41 485 BCC patients. Median follow-up time for the national data and regional data ranged between 4.0 and 7.8 years. Large differences in age were present in the different cohorts with the majority of the melanoma patients occurring in the younger age groups, the majority of the SCC patients in the older age groups and the majority of the BCC patients in the middle two age groups (Table 1) . First melanomas were most frequently located on the trunk in males (47% in the NCR data, 50% in the ECR data) and legs in females (respectively 39% and 37%), a first KC was most frequently located on the head or neck (range 58-76%). In the majority of the cases, subsequent cutaneous malignancies of a different type occurred within the first 5 years after the diagnosis of the first malignancy. However, 12-21% of the subsequent tumours were diagnosed 11-21 years after the first diagnosis.
Cumulative risk
The 21-year cumulative risk of getting a subsequent melanoma after a first SCC or BCC was, respectively, 1.7% and 1.3% for males and 1.3% and 1.2% for females; the 21-year CR of getting a subsequent SCC after a first melanoma, or BCC was 4.6% and 9.3% for males and 2.6% and 4.1% for females; the 21-year CR of getting a subsequent BCC after a first melanoma, or SCC was, respectively, 13.2% and 27.8% for males and 14.9% and 21.1% for females (Table 2 ). Cumulative risk of a different subsequent cutaneous malignancy was consistently higher for males than for females, except for the BCC after melanoma tumour combination (Table 2) .
Standardized incidence ratio (SIR) and absolute excess risk (AER)
SIRs of developing a subsequent primary different cutaneous malignancy were highest in the first year after the first diagnosis for all groups (SIRs 5.0 [95% CI = 3.6-6.9]-13.4 [10.5-17.1]) but remained significantly elevated up to 21 years after the first skin cancer diagnosis (Tables 3-5 ). The follow-up SIRs showed similar trends in the different tumour combinations. The different age categories had SIRs of approximately 3-6, except for the BCC and SCC tumour combination which had SIRs of 6-12.
AERs were highest in the first year after the first melanoma or KC and fluctuated over follow-up time. The AERs of subsequent BCCs were highest, followed by subsequent SCCs and subsequent melanomas (Tables 3-5) .
Discussion
This large population-based study investigating risks of developing a different subsequent cutaneous malignancy after an initial skin cancer showed high-cumulative risks of mainly KC and markedly increased relative and absolute risks of all tumour combinations. These increased risks persist for more than 10 years after the first skin cancer diagnosis. This is the first study reporting detailed long-term cumulative risks of a subsequent different cutaneous malignancy. The cumulative risks are in line with the averaged cumulative risks in the two meta-analyses (mean 20-year CR of a subsequent BCC or SCC in melanoma patients were, respectively, 14.0% and Risks of a different cutaneous malignancy 4.0%; mean 5-year CR of BCC after SCC was 39.3%; no 5-year CR was available for the other tumour combinations), but only 1 or 2 studies contributed to this meta-analyses. 4, 5 In this study, the SIRs ranged between 3.2 and 6.7 which is somewhat higher than the recently published pooled SIRs of a different subsequent cutaneous malignancy (range SIR between 2.4 and 4.6). 4, 5 However, as SIRs are strongly determined by underlying incidence rates (shared risk factors or increased detection), 10 which are high in the Netherlands, [11] [12] [13] [14] it is difficult to compare SIRs between populations. SIRs will be lower if the background incidence is high, this was illustrated in the meta-analysis for the pooled SIRs of the melanoma after melanoma tumour combination (pooled SIR: Australia 7 vs. USA 12 vs. Europe 14.0 4 ). The follow-up SIRs in this study remained elevated for more than 20 years (statistically significant higher than 1) and therefore indicate a 'lifelong' increased risk. Recent studies 6,15-20 did not report risks over different follow-up periods, and no cumulative risks over time were reported. Toth et al. 16 described SIRs of KC after melanoma for a relatively small Hungarian cohort of patients with a 5-year study period (SIR 15.6-17.6). Larger cohorts described skin cancer patients from Canada with SIRs of KC after melanoma (4.2) and melanoma after KC (3.6), 15 a SIR of approximately 3 was reported for the SCC and melanoma tumour combination in Norway. 17 Two large USA cohorts, including the Health Professionals Follow-up Study (HPFS) and the Nurses' Health Study (NHS), reported twofold increase relative risks of a subsequent melanoma after a KC. 18 Dominguez et al. 20 reported a probability density model of a subsequent non-melanoma skin cancer and Asgari et al. 19 reported crude incidence rates and hazard ratios of SCC with data of the Northern California Cancer Registry, but, in our opinion, relative risk or cumulative risk give more useful clinical information. Using single-and multiple-failure models, Wehner et al. 21 found that risks of new KC over time are substantially lower after a first lifetime KC diagnosis than after a non-first KC diagnosis. In contrast to our findings, a relative small Australian study concluded that 'the majority of patients are prone to exclusively develop one type of skin cancer'. 22 A small sample size and young study population (mean age 46 years, and thus not yet reaching the age with highest skin cancer incidences) could explain this difference. However, previous studies in the Netherlands also found high risks of developing a subsequent BCC after a BCC 23 and a subsequent melanoma after a melanoma. 8 The burden of subsequent cutaneous malignancies may be better illustrated by the differences in AER (BCC > SCC > melanoma), because SIRs of the different tumour combinations were relatively similar. The high AERs of subsequent BCCs points to increased diagnosis of BCCs during follow-up visits and possible overdiagnosis. Strengths of this study are the large skin cancer cohorts including histopathological confirmed melanoma, SCC and BCC patients with a long follow-up period (total 21 years) and the population-based character of the risk estimates (cumulative risks, relative and absolute risks) of a subsequent skin cancer of a different type stratified by age and follow-up period. This study presents the most detailed data and describes one of the largest cohorts currently available to investigate likelihood of skin tumour combinations. Limitations are the absence of information concerning phenotypic characteristics of patients, use of immunosuppressive medication, family history and genetic susceptibility.
High incidence of a subsequent different skin cancer in a group of skin cancer patients might be related to shared risk factors, but also to increased patients' and doctors' awareness, diagnostic bias and completeness of the registry. 24 Slowly growing tumours are more likely to be early detected during follow-up through this mechanism, illustrating selection bias. The high numbers of subsequent skin cancers may partly be due to increased surveillance because of follow-up visits, during which some lesions (probably mostly BCCs and thin melanomas), which under other circumstances may had gone undetected, will be diagnosed. Indications for this phenomenon to occur are indeed present in our data; we found that the majority of the subsequent skin cancers were found in the first 5 years after the first diagnosis (52-66%) when the most follow-up visits are scheduled.
Recommendations of follow-up of skin cancer patients are complex to formulate, and they are not based on randomized clinical trials. The Dutch melanoma guideline advises up to 5 years follow-up for patients with a melanoma staged 1B or higher and annual follow-up visits for familial melanoma patients. 25 The current Dutch Basal cell carcinoma guideline (version 1 May 2014 26 ) advises to educate patients about future risk of subsequent skin cancers, lifelong examinations Table 4 Standardized incidence ratio (SIR and 95% confidence intervals) and absolute excess risk (AER, per 10 000 person-years) of subsequent primary basal cell carcinomas and melanomas after, respectively, melanomas (n = 2422 males + 3354 females) and basal cell carcinomas (n = 20 118 males + 21 367 females) in different follow-up periods and age categories. were not advised for most patients. High-risk patients (basal cell nevus syndrome, immunosuppressive medication use and patients with extensive actinic damage) are advised to have annual full-skin examinations (or more frequent if needed).
26
The Dutch SCC guideline advises 5 year of follow-up, based on the fact that most recurrences and subsequent primary SCCs were detected in the first 5 years after diagnosis.
27
Internationally, no consensus is available about follow-up strategies for multiple cutaneous malignancies, but the growing group of multiple cutaneous malignancy patients may need a more evidence-based advice of follow-up. It is also important to focus on patients' compliance of follow-up guidelines 28 because it may point to early detection on the one hand and the less favourable overdiagnosis on the other hand.
Occurrence of multiple skin cancers might be partly caused by the high use of sunbeds 29, 30 and excessive UV seeking behaviour among some Caucasians. 31 35 as well as intense screening 34 will also be of influence. However, individual effects are difficult to examine due to field cancerization of the skin and screening effects. Future mechanistic studies need to focus on occurrence of multiple cutaneous malignancies to identify high-risk patients which may be candidates for chemoprevention and more intensive follow-up. 36, 37 In conclusion, the risk of developing a subsequent different cutaneous malignancy is elevated for at least 20 years after the first diagnosis suggesting a shared and multifactorial risk profile leading to field cancerization. In addition to adverse effects of excessive UV exposure, patients and physicians need to be educated of the high and persistent (lifelong) risk of developing a subsequent skin cancer. The challenge for the future is to stratify high-and low-risk patients for subsequent skin cancers to provide personalized care. Sun protection should be recommended, also for melanoma patients with respect to prevention of other epithelial skin cancers.
